VarilrixTM

also known as Oka-RIT · Varilrix

today NCT00792623 · Ph 2

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00792623	Sep 2003 → Sep 2007	chickenpox	GlaxoSmithKline	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT00751348 Comparator	Oct 2008 → May 2010	measles, mumps infectious disease, rubella, varicella zoster infection	GlaxoSmithKline	Completed	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	VarilrixTM	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00751348 ↗ 1 NCT00792623 ↗
Known as	Oka-RIT	“Varilrix(™) [Oka-RIT]; GlaxoSmithKline Vaccines” PMID 25272081 ↗ Oct 2014
Known as	Varilrix	“who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper...” NCT00751348 ↗
Modality	Vaccine	“Varilrix™ vaccine” NCT00751348 ↗
Route	Subcutaneous	“Subcutaneous injection” NCT00792623 ↗